Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
Naveen Pemmaraju, Jacqueline S. Garcia, Jalaja Potluri, Jason G. Harb, Yan Sun, Paul Jung, Qin Q. Qin, Srinivas K. Tantravahi, Srđan Verstovšek, Claire Harrison
Topics & Concepts
MedicineRuxolitinibMyelofibrosisInternal medicinePost-hoc analysisTolerabilityCohortInternational Prognostic Scoring SystemClinical endpointOncologyAnemiaPhases of clinical researchBone marrowClinical trialMyelodysplastic syndromesAdverse effectMyeloproliferative Neoplasms: Diagnosis and TreatmentMultiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research